Christopher Hite gains 24,263 Royalty Pharma (RPRX) shares via equity award

Rhea-AI Filing Summary

Royalty Pharma plc executive Christopher Hite reported an exempt equity award rather than an open-market trade. On May 6, 2026, an entity associated with him, SCH Investment Partners LLC, acquired 24,263 Class A Ordinary Shares at $0.00 per share in connection with the settlement of Equity Performance Awards, treated as exempt under Rule 16b-3. Following this award, SCH Investment Partners LLC held 709,399 Class A Ordinary Shares indirectly. A separate entry shows 70,000 Class A Ordinary Shares held directly as of the same date, recorded as a holding entry without a reported purchase or sale.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Hite Christopher

Role EVP & Vice Chairman

Type	Security	Shares	Price	Value
Grant/Award	Class A Ordinary Shares	24,263	$0.00	--
holding	Class A Ordinary Shares	--	--	--

Holdings After Transaction: Class A Ordinary Shares — 709,399 shares (Indirect, By SCH Investment Partners LLC); Class A Ordinary Shares — 70,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Awarded shares: 24,263 Class A Ordinary Shares Award price per share: $0.00 per share Indirect holdings after award: 709,399 Class A Ordinary Shares +1 more

4 metrics

Awarded shares 24,263 Class A Ordinary Shares Exempt acquisition via Equity Performance Awards settlement on May 6, 2026

Award price per share $0.00 per share Grant, award, or other acquisition of Class A Ordinary Shares

Indirect holdings after award 709,399 Class A Ordinary Shares Indirectly held by SCH Investment Partners LLC after exempt acquisition

Directly held shares entry 70,000 Class A Ordinary Shares Direct holdings line for Christopher Hite as of May 6, 2026

Key Terms

Rule 16b-3, Equity Performance Awards, Class A Ordinary Shares, indirect ownership

4 terms

Rule 16b-3 regulatory

"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares"

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

Equity Performance Awards financial

"in connection with the settlement of Equity Performance Awards"

Class A Ordinary Shares financial

"Class A Ordinary Shares of the Issuer in connection with the settlement"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

indirect ownership financial

"nature_of_ownership: By SCH Investment Partners LLC"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hite Christopher

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 E. 59TH STREET

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Vice Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	05/06/2026		A		24,263(1)	A	$0	709,399	I	By SCH Investment Partners LLC
Class A Ordinary Shares								70,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 866,410 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,238,789 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.

	/s/ Sean Weisberg, as Attorney-in-Fact for Christopher Hite	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Royalty Pharma (RPRX) report for Christopher Hite?

Royalty Pharma reported an exempt equity award for Christopher Hite. SCH Investment Partners LLC, an entity associated with him, acquired 24,263 Class A Ordinary Shares at $0.00 per share as part of settling Equity Performance Awards, increasing its indirect holdings.

How many Royalty Pharma (RPRX) shares were acquired through the latest equity award?

The equity award involved 24,263 Class A Ordinary Shares. These shares were acquired at $0.00 per share by SCH Investment Partners LLC in connection with the settlement of Equity Performance Awards and are treated as an exempt acquisition under Rule 16b-3.

What are Christopher Hite’s indirect Royalty Pharma (RPRX) holdings after this Form 4?

After the reported award, SCH Investment Partners LLC held 709,399 Class A Ordinary Shares indirectly linked to Christopher Hite. This figure reflects the position following the 24,263-share exempt acquisition tied to the settlement of Equity Performance Awards on May 6, 2026.

Does the Royalty Pharma (RPRX) Form 4 show any open-market buying or selling?

The Form 4 does not show open-market buying or selling. It reports an exempt acquisition of 24,263 Class A Ordinary Shares at $0.00 per share related to Equity Performance Awards, plus a separate holding entry of 70,000 directly held shares without a trade.

How many Royalty Pharma (RPRX) shares does Christopher Hite hold directly in this filing?

The filing lists 70,000 Class A Ordinary Shares as directly held by Christopher Hite. This line is categorized as a holding entry, with no associated purchase or sale transaction reported for these directly held shares on the disclosed date.